Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699555 | 0.87 | HTT (0.52) | SMN1; SMN2HTTNPSR1CNR1MAPT | |
| SCHEMBL13699645 | 0.86 | MEN1 (0.43) | SMN1; SMN2HTTLMNAALDH1A1MEN1 | |
| SCHEMBL13699641 | 0.84 | AKR1C3 (0.50) | SMN1; SMN2HTTMAPTLMNAALDH1A1 | |
| SCHEMBL13699633 | 0.84 | AKR1C3 (0.48) | SMN1; SMN2HTTCNR1MAPTLMNA | |
| SCHEMBL4154819 | 0.81 | CNR1 (0.48) | SMN1; SMN2HTTNPSR1CNR1LMNA | |
| SCHEMBL13699635 | 0.81 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL4177222 | 0.79 | CNR1 (0.47) | SMN1; SMN2HTTNPSR1CNR1LMNA | |
| SCHEMBL38661618 | 0.79 | MEN1 (0.46) | SMN1; SMN2HTTNPSR1CNR1LMNA | |
| SCHEMBL1458941 | 0.79 | SMN1; SMN2 (0.70) | SMN1; SMN2HTTNPSR1MAPTLMNA | |
| SCHEMBL13699644 | 0.76 | AKR1C3 (0.49) | SMN1; SMN2MAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | SMN1; SMN2 422/4885HTT 2006/4885NPSR1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.